The role of PAMPs in liver damage in metabolic-associated Steatotic liver disease (MASLD—previously named non-alcoholic fatty liver disease, NAFLD) is substantiated by preclinical investigations revealing an attenuation of hepatic steatosis, inflammation, and fibrosis in mice deficient in toll-like receptors 4 (TLR-4) or 9 (TLR-9) under conditions of a high-fat or choline-deficient diet [23,24,25]. This evidence concerns the gene TLR9 and fatty liver disease.